Findlay Park Partners LLP Has $111.49 Million Stake in Danaher Corporation $DHR

Findlay Park Partners LLP reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 3.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 564,400 shares of the conglomerate’s stock after selling 20,400 shares during the quarter. Findlay Park Partners LLP owned approximately 0.08% of Danaher worth $111,492,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of DHR. Red Tortoise LLC raised its stake in shares of Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after purchasing an additional 98 shares in the last quarter. Costello Asset Management INC acquired a new position in Danaher in the first quarter worth approximately $41,000. Ramirez Asset Management Inc. acquired a new position in Danaher in the second quarter worth approximately $40,000. Strengthening Families & Communities LLC raised its position in Danaher by 81.4% during the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock valued at $52,000 after acquiring an additional 114 shares in the last quarter. Finally, Saudi Central Bank bought a new stake in Danaher in the first quarter worth approximately $52,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Down 1.0%

Shares of DHR stock opened at $228.41 on Thursday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The firm has a market cap of $161.33 billion, a PE ratio of 47.09, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The stock has a 50 day moving average of $210.88 and a 200-day moving average of $202.81.

Danaher (NYSE:DHR) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm posted $1.71 earnings per share. Danaher’s revenue was up 4.4% compared to the same quarter last year. On average, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,248 shares of company stock worth $6,609,663 over the last three months. Company insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DHR. Evercore ISI raised their price target on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Redburn Partners set a $220.00 target price on shares of Danaher in a research report on Wednesday, October 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, Bank of America reduced their target price on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.